Multi-dose phase study of Dalfampridine in patients with post-stroke walking difficulty

Trial Profile

Multi-dose phase study of Dalfampridine in patients with post-stroke walking difficulty

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs Fampridine (Primary)
  • Indications Stroke complications
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Nov 2016 According to an Acorda Therapeutics media release, the company has decided to discontinue further development of dalfampridine for the treatment of post-stroke walking difficulties based on results of MILESTONE trial.
    • 22 Nov 2016 According to an Acorda Therapeutics media release, status changed from planning to withdrawn prior to enrolment.
    • 28 Jul 2016 Results from this trial are expected in the fourth quarter of 2016, according to an Acorda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top